UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Address of Principal Executive Offices) (Zip Code) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-34673 CORMEDIX INC. (Exact Name of Registrant as Specified in Its Charte ...

Exhibit 99.1 SS Innovations Reports Second Quarter 2025 Financial Results Record Quarterly Revenue of $10.0 Million Driven by Higher SSi Mantra 3 Unit Sales Gross Profit More than Tripled, Driven by Gross Margin Expansion and Revenue Growth ● Revenue increased 85.6% to $15.1 million from $8.1 million in the first half of 2024. ● Gross margin expanded to 46.3% from 26.6% in the first half of 2024. ● Gross profit rose 223.3% to $7.0 million from $2.2 million in the first half of 2024. ● Net loss of $5.9 milli ...

FOR THE QUARTERLY PERIOD ENDED June 30, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 814-00852 SuRo Capital Corp. (Exact name of registrant as specified in its charter) Maryland 27-4443543 (State or other jurisdiction of incorporation or organization) 64 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 WASHINGTON, DC 20549 FORM 10-Q (Mark One) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39691 BARK, INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organizat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-42272 MBX Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) (317) 659-0 ...

Table of Contents OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 001-40839 QT Imaging Holdings, Inc. (Exact name of registrant as specified in its charter) _________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly p ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 001-40839 QT Imaging Holdings, Inc. (Exact name of registrant as specified in its charter) ...

[Financial and Operational Highlights](index=1&type=section&id=Financial%20and%20Operational%20Highlights) Aemetis reported increased Q2 2025 revenue to $52.2 million, driven by India biodiesel and Dairy RNG, alongside strategic biogas and India IPO preparations Q2 2025 Key Financial Metrics | Metric | Value ($) | Note | | :--- | :--- | :--- | | **Revenues** | $52.2M | Increased $9.3M from Q1 2025 | | **Aemetis Biogas Revenue** | $3.1M | From 11 operating digesters | | **Operating Loss** | Improved by $4.9M | Compared to Q1 2025, due to lower SG&A | - The increase in revenue was primarily driven by the California Ethanol and Dairy RNG segments, along with new orders for the India Biodiesel business from Oil Marketing Companies[3](index=3&type=chunk)[5](index=5&type=chunk) - Strategic developments include the appointment of a new CFO for the India subsidiary, targeting a public listing in early **2026**[5](index=5&type=chunk) - Aemetis Biogas signed a **$27 million** agreement with NPL for H₂S and compression units for **15** dairy digesters and received CARB approval for **7** new LCFS pathways[5](index=5&type=chunk) - The company anticipates increased income and cash flow from Section 45Z production tax credits and cost reductions from the mechanical vapor recompression project in its California Ethanol segment[3](index=3&type=chunk)[4](index=4&type=chunk) [Financial Results](index=2&type=section&id=Financial%20Results) Aemetis reported Q2 2025 revenues of $52.2 million, a decrease from Q2 2024, but improved operating and net losses for both the quarter and first half [Financial Results for the Three Months Ended June 30, 2025](index=2&type=section&id=Financial%20Results%20for%20the%20Three%20Months%20Ended%20June%2030%2C%202025) Q2 2025 revenues decreased to $52.2 million year-over-year, while operating and net losses improved to $10.7 million and $23.4 million respectively, despite a wider gross loss Q2 2025 vs Q2 2024 Financial Comparison | Metric | Q2 2025 ($) | Q2 2024 ($) | Change ($) | | :--- | :--- | :--- | :--- | | **Revenues** | $52.2M | $66.6M | ($14.4M) | | **Gross Loss** | ($3.4M) | ($1.8M) | ($1.6M) | | **Operating Loss** | ($10.7M) | ($13.6M) | $2.9M Improvement | | **Net Loss** | ($23.4M) | ($29.2M) | $5.8M Improvement | - SG&A expenses decreased significantly to **$7.3 million** from **$11.8 million** year-over-year, primarily due to a one-time **$3.6 million** loss on asset disposals in 2024[7](index=7&type=chunk) - Cash at quarter-end was **$1.6 million**, up from **$900 thousand** at the end of 2024, with **$3.6 million** invested in capital projects during the quarter[10](index=10&type=chunk) [Financial Results for the Six Months Ended June 30, 2025](index=2&type=section&id=Financial%20Results%20for%20the%20Six%20Months%20Ended%20June%2030%2C%202025) H1 2025 revenues decreased to $95.1 million due to India contract delays, while gross and operating losses widened, but net loss improved to $47.9 million H1 2025 vs H1 2024 Financial Comparison | Metric | H1 2025 ($) | H1 2024 ($) | Change ($) | | :--- | :--- | :--- | :--- | | **Revenues** | $95.1M | $139.2M | ($44.1M) | | **Gross Loss** | ($8.4M) | ($2.4M) | ($6.0M) | | **Operating Loss** | ($26.2M) | ($23.1M) | ($3.1M) | | **Net Loss** | ($47.9M) | ($53.4M) | $5.5M Improvement | - The lower revenue in H1 2025 was primarily due to delays in receiving contracts from government-owned Oil Marketing Companies in India[11](index=11&type=chunk) - Total investments in capital projects during H1 2025 amounted to **$5.4 million**, with **$4.1 million** dedicated to Aemetis Biogas projects[14](index=14&type=chunk) [Company Overview and Forward-Looking Statements](index=2&type=section&id=Company%20Overview%20and%20Forward-Looking%20Statements) Aemetis is a renewable energy company producing RNG, fuels, and biochemicals, with operations in California and India, and developing SAF, while reporting non-GAAP measures and forward-looking statements - Aemetis operates a California biogas digester network (RNG), a **65 MGY** ethanol plant in California, an **80 MGY** biodiesel facility in India, and is developing a SAF/renewable diesel biorefinery[15](index=15&type=chunk)[16](index=16&type=chunk) - The company defines Adjusted EBITDA as net loss adjusted for interest, taxes, depreciation, amortization, accretion, and share-based compensation[17](index=17&type=chunk) - The release contains forward-looking statements regarding growth plans, market trends, project development, and capital raising, subject to various risks and uncertainties[19](index=19&type=chunk) [Consolidated Financial Statements](index=4&type=section&id=Consolidated%20Financial%20Statements) This section presents unaudited consolidated financial statements, detailing Q2 and H1 2025 operations, and the balance sheet as of June 30, 2025, showing asset and liability changes [Consolidated Condensed Statements of Operations](index=4&type=section&id=CONSOLIDATED%20CONDENSED%20STATEMENTS%20OF%20OPERATIONS) Aemetis reported a net loss of $23.4 million for Q2 2025 and $47.9 million for H1 2025, showing improvement compared to prior-year periods, with a Q2 2025 loss per share of $0.41 Consolidated Condensed Statements of Operations (unaudited, in thousands, except per share data) | | For the three months ended June 30, (in thousands) | For the six months ended June 30, (in thousands) | | :--- | :--- | :--- | :--- | :--- | | | **2025** | **2024** | **2025** | **2024** | | **Revenues** | $52,243 | $66,561 | $95,129 | $139,195 | | Cost of goods sold | 55,598 | 68,367 | 103,564 | 141,613 | | **Gross loss** | **(3,355)** | **(1,806)** | **(8,435)** | **(2,418)** | | SG&A expenses | 7,319 | 11,800 | 17,794 | 20,650 | | **Operating loss** | **(10,674)** | **(13,606)** | **(26,229)** | **(23,068)** | | Interest expense | 12,330 | 11,724 | 26,023 | 22,237 | | Accretion of Series A preferred units | 2,032 | 3,477 | 4,311 | 6,788 | | **Net loss** | **$(23,395)** | **$(29,174)** | **$(47,924)** | **$(53,405)** | | **Net loss per common share (Basic & Diluted)** | **$(0.41)** | **$(0.66)** | **$(0.87)** | **$(1.24)** | [Consolidated Condensed Balance Sheets](index=5&type=section&id=CONSOLIDATED%20CONDENSED%20BALANCE%20SHEETS) As of June 30, 2025, Aemetis reported total assets of $240.0 million, total liabilities of $529.3 million, and a stockholders' deficit of $289.3 million, with a notable increase in current long-term debt Consolidated Condensed Balance Sheets (in thousands) | | June 30, 2025 (Unaudited, in thousands) | December 31, 2024 (in thousands) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $1,645 | $898 | | Total current assets | $20,086 | $44,696 | | Property, plant and equipment, net | $204,641 | $199,392 | | **Total assets** | **$240,016** | **$259,302** | | **Liabilities and Stockholders' Deficit** | | | | Current portion of long term debt | $247,615 | $63,745 | | Total current liabilities | $321,927 | $143,968 | | Total long term liabilities | $207,344 | $379,262 | | Total stockholders' deficit | $(289,255) | $(263,928) | | **Total liabilities and stockholders' deficit** | **$240,016** | **$259,302** | [Non-GAAP Reconciliation and Operational Metrics](index=6&type=section&id=Non-GAAP%20Reconciliation%20and%20Operational%20Metrics) This section presents non-GAAP Adjusted EBITDA reconciliation and operational metrics, showing a slight improvement in Q2 2025 Adjusted EBITDA loss and varied production volumes across segments [Reconciliation of Adjusted EBITDA to Net Income/(Loss)](index=6&type=section&id=RECONCILIATION%20OF%20ADJUSTED%20EBITDA%20TO%20NET%20INCOME%2F%28LOSS%29) Aemetis reported an Adjusted EBITDA loss of $5.8 million for Q2 2025, a slight improvement, but a $16.4 million loss for H1 2025, a deterioration, with reconciliation details provided Reconciliation of Adjusted EBITDA to Net Loss (unaudited, in thousands) | | For the three months ended June 30, (in thousands) | For the six months ended June 30, (in thousands) | | :--- | :--- | :--- | :--- | :--- | | | **2025** | **2024** | **2025** | **2024** | | **Net loss** | **$(23,395)** | **$(29,174)** | **$(47,924)** | **$(53,405)** | | Total adjustments | 17,627 | 23,268 | 31,494 | 42,749 | | **Adjusted EBITDA** | **$(5,768)** | **$(5,906)** | **$(16,430)** | **$(10,656)** | [Production and Price Performance](index=7&type=section&id=PRODUCTION%20AND%20PRICE%20PERFORMANCE) Q2 2025 production and sales varied by segment, with California Ethanol volumes decreasing, Dairy RNG increasing, and India Biodiesel sales significantly dropping due to contract delays Q2 2025 vs Q2 2024 Production and Sales Comparison | Segment | Metric | Q2 2025 (Units) | Q2 2024 (Units) | | :--- | :--- | :--- | :--- | | **California Ethanol** | Gallons sold (millions) | 13.8 | 14.8 | | **CA Dairy RNG** | MMBtu sold (thousands) | 106.4 | 88.0 | | **India Biodiesel** | Metric tons sold (thousands) | 9.4 | 20.4 | Q2 2025 vs Q2 2024 Average Price Comparison | Segment | Metric | Q2 2025 ($) | Q2 2024 ($) | | :--- | :--- | :--- | :--- | | **California Ethanol** | Avg. sales price/gallon | $2.01 | $1.99 | | **CA Dairy RNG** | Avg. price per MMBtu | $2.75 | $2.19 | | **India Biodiesel** | Avg. sales price/metric ton | $1,010 | $1,162 |

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: KVH Industries, Inc. Chris Watson 401-845-2441 IR@kvh.com KVH Industries Reports Second Quarter 2025 Results MIDDLETOWN, RI, August 7, 2025 — KVH Industries, Inc. (Nasdaq: KVHI), reported financial results for the quarter ended June 30, 2025 today. The company will hold a conference call to discuss these results at 9:00 a.m. ET today, which can be accessed at investors.kvh.com. Following the call, a replay of the webcast will be available through the company's web ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) 321 Arsenal Street, Suite 101 Watertown, Massachusetts 02472 (Address of principal executive offices) (Zip Code) Delaware 85-1612845 (I.R. ...